Brief: Ocumension Therapeutics Says Hainan Medical Product Administration Granted Approval To Group's OT-502
07/07/2021 10:19
July 7 (Reuters) - Ocumension Therapeutics 1477.HK :
* HAINAN MEDICAL PRODUCT ADMINISTRATION GRANTED APPROVAL TO
GROUP'S OT-502
* APPROVAL ALLOWS OT-502 TO BE IMPORTED AS FOREIGN DRUGS NOT
YET
APPROVED IN CHINA FOR URGENT MEDICAL NEEDS IN HAINAN PROVINCE
* APPROVAL MAY POTENTIALLY ACCELERATE NDA SUBMISSION OF
OT-502 IN
CHINA
Source text for Eikon: ID:nHKSbfQBWj
Further company coverage: 1477.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ocumension Therapeutics
See all newsBrief: Ocumension Therapeutics Says NMPA Accepts NDA For OT-301 (NCX 470, Bimatoprost Grenod)
Brief: Ocumension Therapeutics Says Dexamethasone Intraocular Suspension Application Accepted By NMPA
Brief: Ocumension Therapeutics Says HY Adjusted Net Loss Rmb57.5 Million
China's Ocumension Therapeutics H1 revenue surges on higher ophthalmic product sales
Ocumension jumps most in three months on China nod for new drug application